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biloba, and pycnogenol. Half of the studies focused on breast cancer. Most resulted in 
statistically non-significant findings, but two studies of erythpoietin and the pycnog-
enol trial had significant results. All 3 of the non-pharmacological studies focused on 
patients with breast cancer, two using a form of cognitive-behavior therapy (CBT) and 
the third studying a yoga program. CONCLUSIONS: The review found a large number 
of studies documenting the problem of CRCD, discussing innovative ways of measur-
ing the extent of the cognitive impairment, and describing etiological theories, such 
as the relationship of CRCD to fatigue and anemia. However, there was a paucity of 
well-designed, sufficiently powered studies of potential treatments, given the extent 
of the problem and its impact on patient functioning. This is an area of clear patient 
need which warrants further scientific study.
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OBJECTIVES: To evaluate short and long term effects of hypofractioned radiation 
therapy in women with early stage breast cancer, after undergoing breast con-
servative surgery. METHODS: We searched for randomized controlled trials in 
Embase, Medline, Cochrane Library and Lilacs comparing unconventional versus 
conventional fractioning. The authors performed data extraction independently. 
Disagreements were resolved by consensus. Random-effects risk ratios (RR) were 
calculated comparing patients randomized to unconventional with those to con-
ventional fractioning. Periods before and after five years of treatment were consid-
ered. RESULTS: Five trials reported on 7.802 women. The studies were of medium to 
high quality. Unconventional fractionation did not affect, until five years and after 
five years, respectively: (1) local recurrence RR 0.90 (95% CI 0.68 to 1.18, P = 0.44) and 
RR 0.98 (95% CI 0.83 to 1.17, P = 0.86); (2) distant recurrence (RR) 1.04 (95% CI 0.73 to 
1.46, P = 0.84) and RR 1.02 (95% CI 0.79 to 1.32, P = 0.88); (3) mortality RR 0.89 (95% 
CI 0.77 to 1.05, P = 0.16) and RR 0.96 (95% CI 0.89 to 1.08, P = 0.48); (4) disease-free 
survival RR 0.96 (95% CI 0.78 to 1.18, P = 0.69) and RR 0.96 (95% CI 0.84 to 1.09, P = 
0.49); (5) cardiac ischemia RR 0.73 (95% CI 0.34 to 1.57, P = 0.42) and RR 0.61 (95% CI 
0.33 to 1.15, P = 0.13); (6) rib fracture RR 1.02 (95% CI 0.25 to 4.20, P = 0.98) and RR 1.08 
(95% CI 0.26 to 4.53, P = 0.91); (7) pulmonary fibrosis RR 2.42 (95% CI 0.50 to 11.71, 
P = 0.27) and RR 0.97 (95% CI 0.89 to 11.21, P = 0.07). CONCLUSIONS: Using hypof-
ractioned radiotherapy regimens does not affect any of the outcomes analyzed in 
women with early stage breast cancer, after undergoing breast conservative surgery.
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OBJECTIVES: The purpose of this study was to estimate incidence of and identify fac-
tors associated with cardiotoxicity, defined as heart failure and/or cardiomyopathy, 
and all-cause mortality in breast cancer patients undergoing adjuvant chemotherapy 
or hormones. METHODS: A retrospective, population-based cohort study of 108,672 
women (≥ 66 years of age) newly diagnosed with breast cancer from 2001-2009 was 
conducted using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-
linked database. Adjuvant chemotherapy were classified as mutually exclusive 
groups: trastuzumab-based, anthracycline-based, anthracycline and trastuzumab-
based, taxane-based, and other chemotherapy. Propensity score matching adjusted for 
differences in patient characteristics across treatments. The final sample included a 
total of 11,250 women. Multivariable Cox proportional hazards regression models esti-
mated hazard ratios (HRs) of cardiotoxicity and all-cause mortality with adjustment 
for inverse probability weights, sociodemographics, cancer characteristics, comorbidi-
ties, surgery and radiation, region, and year at diagnosis. RESULTS: Compared with 
hormones, risk of cardiotoxicity was higher in patients treated with anthracycline 
and trastuzumab-based (adjusted HR= 1.87; 95% confidence intervals [CI]= 1.51-2.33), 
trastuzumab-based (HR= 1.32; 95%CI= 1.14-1.52), and anthracycline-based (HR= 1.14; 
95%CI= 1.03-1.27) regimens, respectively. Certain baseline characteristics were sig-
nificant predictors of cardiotoxicity, including demographics (older age (vs. ≤ 70), 
non-Hispanic black), cancer characteristics (advanced stage), comorbidities (cardio-
vascular conditions or renal failure), year at diagnosis, and West region (vs. Northeast). 
Additionally, risk of all-cause mortality was higher in patients treated with taxane-
based (HR= 1.54; 95%CI= 1.43-1.67) regimens compared to hormones. Baseline charac-
teristics including sociodemographics, cancer characteristics, cardiovascular or renal 
failure comorbid conditions, year at diagnosis, and South region were significant pre-
dictors of all-cause mortality (all P< 0.05). CONCLUSIONS: Women with breast cancer 
treated with trastuzumab-based and/or anthracycline-based regimens had increased 
cardiotoxicity risk compared with hormones, while those treated with taxane-based 
regimens had higher rates of all-cause mortality. Types of chemotherapy are associ-
ated with increased risk of cardiotoxicity and all-cause mortality. Practitioners should 
further evaluate treatment and patient characteristics for risk mitigation strategies.
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OBJECTIVES: Although the relationship between diabetes and risk of pancreatic 
cancer are well-documented, limited research has examined whether racial/eth-
nicity differences accounted for the association between diabetes and pancreatic 
cancer. The aims of this study were to 1) assess whether diabetes is associated with 
pancreatic cancer in the elderly Medicare population, and 2) identify if any racial/
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OBJECTIVES: Denosumab is a biologic approved in June 2010 to treat bone tumors 
and hypercalcemia of malignancy. This study characterizes bone-related safety sig-
nals of subtrochanteric atypical femoral fractures (SAF) and osteonecrosis of the 
jaw (ONJ) in relation to denosumab therapy. METHODS: The FDA Adverse Event 
Reporting System was used to detect signals of SAF and ONJ in relation to deno-
sumab therapy. Adverse event reports submitted between July 2010 and December 
2013 were retrieved and disproportional reporting of SAF and ONJ was calculated by 
Empirical Bayes Geometric Mean (EBGM). Denosumab-event pairs with EBGM 95% 
confidence interval lower limit ≥ 2.0 are considered signals of SAF and ONJ excess 
reporting compared to other drugs in the database. Events were defined by the 
Preferred Terms of the Medical Dictionary for Regulatory Activities, and denosumab 
was defined by the Anatomical Chemical Therapeutic Classification. RESULTS: A 
total of 26,216 adverse event reports submitted for denosumab during the analysis 
period, corresponding to 30 for SAF and 721 for ONJ. Denosumab was significantly 
associated with more than expected reporting of SAF (EBGM= 17.5, 95%CI= 9.67-30.0) 
and ONJ (EBGM= 26.9, 95%CI= 20.1-35.9) compared to other drugs. The majority of 
denosumab users who experienced both events were females, and average age was 
69 years (SAF SD= 9.5; ONJ SD= 11.3). 12 SAF and 65 ONJ events lead to hospitaliza-
tion; 25 and 14 ONJ events contributed to patient disability and death, respectively. 
Other factors could have lead to these serious outcomes, including comedications 
and comorbidities. CONCLUSIONS: SAF and ONJ are potential risks of denosumab 
therapy. Patients with thigh or hip pain should seek immediate medical help, and 
periodic dental and maxillofacial evaluations should be performed before and dur-
ing denosumab therapy. Pharmacoepidemiologic studies are recommended to fur-
ther characterize these risks, as some patients were treated with other medications, 
including systemic corticosteroids at the time of event occurrence.
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OBJECTIVES: Sipuleucel-T is an autologous active cellular immunotherapy designed 
to reduce the risk of death in patients with prostate cancer. The aim of this study was 
to evaluate the safety of Sipuleucel-T for patients with prostate cancer. METHODS: 
PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were 
searched through January 10, 2015. Criteria for inclusion were randomized, pla-
cebo-controlled clinical trials on Sipuleucel-T, patients receiving three infusions, 
36 months follow-up and the availability of outcomes data for adverse events. The 
primary outcome was the total number of adverse events. Secondary outcomes 
examined eighteen specified adverse events. Two investigators selected studies 
independently and assessed the quality of studies using the Jadad scale. Point esti-
mates with a 95% confidence interval were generated. Fixed-effects or random 
random-effects models were based on the evaluation of heterogeneity. RESULTS: 
Five clinical trials encompassing 1031 patients were included. The overall adverse 
events relative risk (RR) was 1.02 (95% CI 1.00 to 1.05, p= 0.091). For the secondary 
outcomes, differences were detected between Sipuleucel-T and placebo on chills (RR 
4.87; 95% CI 2.50 to 6.78, p= 0.000; 904 patients), fatigue (RR 1.20; 95% CI 1.01 to 1.43, 
p= 0.035; 1031 patients), pyrexia (RR 5.40; 95% CI 1.90 to 15.35, p= 0.002; 1031 patients), 
headache (RR 2.68; 95% CI 1.75 to 4.10, p= 0.000; 1031 patients), influenza like illness 
(RR 3.07; 95% CI 1.48 to 6.36, p= 0.003; 681 patients), myalgia (RR 2.24; 95% CI 1.26 
to 4.00, p= 0.006; 681 patients), nausea (RR 1.40; 95% CI 1.05 to 1.88, p= 0.023; 1031 
patients), vomiting (RR 1.86; 95% CI 1.21 to 2.88, p= 0.005; 856 patients) and dyspnea 
(RR 3.72; 95% CI 1.34 to 10.36, p= 0.012; 350 patients). CONCLUSIONS: Sipuleucel-T 
significantly increased the risk of selected adverse events in patients with prostate 
cancer. Although many adverse events were transient, patients and providers should 
consider the potential risk of treatment with Sipuleucel-T.
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OBJECTIVES: Chemotherapy-related cognitive dysfunction (CRCD), colloquially known 
as ‘chemo fog’ or ‘chemo brain,’ describes the impact of chemotherapy on cogni-
tive functioning in domains ranging from memory to expressive language. CRCD is 
generally attributed to the direct or indirect effects of chemotherapy on the central 
nervous system, may occur at some level of intensity in as many as 75% of patients 
who have undergone chemotherapy, and impacts patient quality of life, educational/
occupational achievement, and social functioning. Management of CRCD includes 
both pharmacological and non-pharmacological therapies. METHODS: To better 
understand the range of treatments that have been studied for CRCD, and their rela-
tive efficacy, a comprehensive review of the published literature was undertaken. A 
MEDLINE search was conducted for relevant sources published in English between 
January 2005 and December 2014. The search was limited to studies describing tri-
als of interventions to manage or treat CRCD using non-pharmacological interven-
tions. RESULTS: Of 161 records retrieved, 11 described interventions targeting CRCD. 
Pharmacological therapies used included erythropoietin, dexmethylphenidate, ginkgo 
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rectal cancer (CRC) after controlling for other risk factors. METHODS: We identified a 
cohort of 37,044 elderly Medicare beneficiaries with incident CRC between 2003 and 
2009 who had colorectal surgery using the SEER-linked Medicare database. T2DM was 
identified using the ICD-9-CM (International Classification of Diseases, 9th Revision, 
and Clinical Modification) codes during the 12-months prior to incident diagnosis 
of CRC. CRC surgery was identified with procedure codes for colon resection, rectal 
resection, and other operations on the intestine including colostomy and ileostomy. If 
individuals with CRC had ICD-9-CM codes indicative of bowel perforation, peritonitis, 
or obstruction, they were considered to have emergency surgery. Chi-square tests 
and logistic regression were used to analyze the association between pre-existing 
T2DMand emergency surgery after adjustments for sex, race/ethnicity, age, cancer 
site, stage, region, and office visits in the 12 months prior to incident cancer. RESULTS: 
Unadjusted rates of emergency surgery were significantly lower among CRC patients 
with pre-existing T2DM compared to CRC patients without diabetes (9.8% vs.11.4%). 
This association, however, was not significant in adjusted analyses. CRC patients 
with highest number of annual office visits were significantly less likely than CRC 
patients with lowest number of annual office visits to receive emergency surgery 
(AOR= 0.69; 95%CI= 0.61, 0.78). Other risk factors for emergency surgery in CRC patients 
were old age (80-84 years: AOR= 1.15, 95%CI= 1.03, 1.29; 85 years and above: AOR= 1.41, 
95%CI= 1.26, 1.58), and late stage at diagnosis (regional stage: AOR= 2.14, 95%CI= 1.99, 
2.31; distant stage: AOR= 2.78, 95%CI= 2.54, 3.05). CRC patients with atherosclerosis 
were less likely to have emergency surgery compared to those without atherosclerosis 
(AOR= 0.89; 95%CI= 0.82, 0.97). CONCLUSIONS: Pre-existing T2DM was not associated 
with emergency surgery after controlling for a comprehensive list of risk factors.
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OBJECTIVES: NCCN guidelines recommend that non-metastatic colorectal cancer 
(CRC) patients receive a comprehensive work-up including detailed imaging studies. 
The purpose of this study was to evaluate physician concordance to NCCN guide-
lines in terms of the receipt of tests and procedures during the 6-month period prior 
to a patient’s CRC diagnosis. METHODS: A large integrated claims database span-
ning January 2008 to September 2013 was used to identify patients ≥ 50 years old 
diagnosed and treated for CRC. Patients were required to be continuously enrolled 
for ≥ 6 months pre- (baseline period) and ≥ 3 months post-diagnosis. Eligible patients 
were stratified into cohorts based on the occurrence and timing of metastatic (M) 
disease: no metastases (NM), ≤ 90 days (M1), and ≥ 90 days (M2) from initial diag-
nosis. Tests evaluated included disease-appropriate CT or MRI, ultrasound, blood 
and fecal screenings, baseline biopsy, CEA, endoscopy, PET-CT, proctoscopy, sig-
moidoscopy, and colonoscopy. RESULTS: There were 15,182 patients meeting study 
criteria, with 77.8% being NM, 11.2% M1, and 11.0% M2. Over 75% of patients had a 
health physical in the baseline period but only 43.3% received fecal or blood-based 
screenings. The most common invasive procedure was colonoscopy, occurring in 
9.6% of M1, 13.7% of M2, and 11.7% of NM patients. Less than 20% of NM patients 
(17.8%) received a chest, abdominal, or pelvic CT or MRI compared to 20.7% of M1 
and 33.8% of M2 patients. Twice as many M2 patients (30.9%) received a CEA test 
compared to 15.1% of M1 and 24.6% of NM patients. Biopsy, ultrasound (including 
endorectal), proctoscopy, and sigmoidoscopy were documented in less than 5% of 
all patients. CONCLUSIONS: In this population of CRC patients, concordance to 
NCCN guidelines was low, with NM patients receiving a lesser degree of complete 
work-up per guidelines compared with M patients.
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OBJECTIVES: While cancer registries such as SEER currently serve as the larg-
est source of cancer epidemiology, recent research (Cogle, et al., 2012) has sug-
gested that these registries may be underreporting AML due to methodological 
limitations. Using a claims-based algorithm, we estimated the incidence of acute 
myeloid leukemia (AML) in the < 65 year-old US population. METHODS: A retro-
spective analysis of claims was performed using 2010-2012 IMS Health LifeLink 
PharMetrics Plus (LifeLink), a longitudinal medical claims dataset comprised of 
adjudicated claims of > 150 million unique enrollees. LifeLink is representative of 
the US commercially-insured population aged ≤ 65. AML diagnoses were identified 
using ICD-9 codes and AML treatments were identified using CPT/HCPCS codes 
and ICD-9-CM infusion codes. Patients with ≥ 2 claims including AML diagnoses 
codes OR one AML medical claim and one AML treatment in 2012 were defined as 
prevalent AML patients. A sub-population of all prevalent AML patients without 
historical AML diagnoses or treatments during the prior two years were identified 
as new (incident) AML patients. Results were stratified by gender and age (< 18, 
18-39, 40-49, 50-59, 60-64 years). RESULTS: The overall 2012 incidence of the < 65 
population was 5.4 per 100,000 (95% CI: 5.2, 5.6), with incidence incrementally 
increasing with age (i.e., lowest in the < 18 cohort [3.2 per 100,000] and highest in 
the 60-64 cohort [12.3 per 100,000]). Incidence among males was slightly higher 
than among females, 5.7 (95% CI: 5.3, 6.0) and 5.2 (95% CI: 4.9, 5.5) per 100,000, 
respectively. Males 60-64 had the highest incidence rate, 13.5 per 100,000 (95% CI: 
11.7, 15.2). CONCLUSIONS: Our 2012 AML incidence estimates are substantially 
higher than published SEER estimates for the < 65 population: 5.4 per 100,000 vs. 
SEER’s 1.8 per 100,000, respectively. Thus, the current AML burden of disease may 
be underestimated, further justifying the need for earlier detection and more 
efficacious treatment options.
ethnicity disparities exist in the association between diabetes and pancreatic can-
cer. METHODS: In a retrospective cross-sectional study, community-dwelling and 
institutionalized Medicare beneficiaries aged 65 or over without health maintenance 
organization enrollment from the Medicare Current Beneficiary Survey (MCBS) from 
2001 to 2010 were included. The outcome of the study was pancreatic cancer; and the 
key explanatory variables were diabetes and race/ethnicity. Potential confounders 
considered included age, gender, education, marital status, income, residence area, 
body mass index (BMI), smoking status, Charlson comorbidity index (CCI), and use 
of preventive services. The International Classification of Diseases-9 codes were 
used to identify the outcome and explanatory variables from the Medicare Part 
A and B claims. Logistic regressions were performed to estimate the association 
between diabetes and pancreatic cancer. RESULTS: A total of 98,966 person-years 
of elderly Medicare beneficiaries were included in the analysis. After controlling 
for potential confounders, the association between diabetes and pancreatic can-
cer was statistically significant (odds ratio [OR], 3.15; 95% confidence interval [CI], 
2.07-4.77). Compared to non-Hispanic whites, non-Hispanic blacks (OR, 0.43; 95% CI, 
0.15-1.20) and Hispanics (OR, 0.78; 95% CI, 0.33-1.85) had similar risks of pancreatic 
cancer. CONCLUSIONS: This study found that diabetes is associated with pancreatic 
cancer in the elderly Medicare population. However, racial/ethnicity differences do 
not explain the association between diabetes and pancreatic cancer.
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OBJECTIVES: The burden of comorbid illness is known to be higher among lung cancer 
patients and it’s also shown to impact survival outcomes. However, the influence of 
comorbidity on in-hospital surgical outcomes among lung cancer patients remains 
unknown. Therefore, this study examined the effect of comorbidity on risk of post-
operative complications, prolonged hospitalization, and in-patient death among lung 
cancer patients following surgery. METHODS: A retrospective analysis of hospital 
discharge data from the 2011 Health Care Utilization Project - Nationwide Inpatient 
Sample (HCUP-NIS) database was performed. Discharges of patients who underwent 
surgery for lung cancer during 2011 were identified. Information about patients and 
hospitals characteristics were obtained. Comorbidities were identified and used to 
calculate Charlson comorbidity index score. Patients were then divided based on these 
scores into four groups: 0, 1, 2, and ≥ 3. Multivariate logistic regression analyses was 
used to examine risk adjusted association between comorbidity score and the study 
outcomes. RESULTS: We identified 19,564 patients’ discharges that meet our inclusion 
criteria. Compared to patients with no comorbid conditions, patients with one or more 
comorbid conditions saw a two-fold increase in the risk of post-operative complica-
tions (p< 0.001). The risk of prolonged hospitalization was also higher among patients 
with a comorbidity score of 1, 2, or ≥ 3, compared to patients with a comorbidity score 
of zero (p< 0.001). Higher comorbidity burden also increased the risk of in-patient 
death by three folds (p< 0.001). CONCLUSIONS: In-hospital outcomes among lung 
cancer patients following surgery are negatively impacted by presence of comorbid 
illness. Post-operative morbidity and mortality among these patients may be reduced 
if their comorbid conditions are managed effectively.
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OBJECTIVES: Some new cancer therapies are associated with prolonged patient 
survival; therefore, management of chronic comorbidities in cancer patients has 
become more important. We sought to measure the prevalence of lipid disorders, 
and other chronic comorbidities, among cancer patients admitted to U.S. hospitals 
over a 14-year period. METHODS: We utilized data from the U.S. National Hospital 
Discharge Surveys from 1996 to 2009. We limited the study to patients ≥ 18 years 
of age with a primary discharge diagnosis of lung, breast, prostate, or colorectal 
cancer (ICD-9-CM codes 162, 174, 185, and 153, respectively). Data weights were 
used to derive national estimates. The prevalence of diabetes (250), ischemic heart 
disease (410-414), heart failure (428), cerebrovascular disease (430-438), and lipid 
disorders (272) was calculated for each year and cancer type. RESULTS: Roughly 
6 million visits were represented over the 14-year study period (lung 2.1, breast 
1.3, prostate 1.3, and colorectal cancer 1.6 million). One-third of patients admit-
ted with cancer had at least one comorbidity, and 8% had at least two comor-
bidities over the entire 14-year study interval; however, the rates of comorbidity 
changed drastically over time—particularly for lipid disorders. Of the patients 
admitted with lung cancer in 1996, only 2% had lipid disorders, compared to 13% 
in 2009. Similar patterns were observed for those patients admitted with breast 
cancer (2% to 17%), prostate cancer (3% to 30%), and colorectal cancer (2% to 12%). 
Prevalence of diabetes and ischemic heart disease also increased, but to a lesser 
extent. CONCLUSIONS: Management of lipid disorders in patients with cancer 
has become increasingly important. U.S. studies focused on improving cancer 
mortality, as well as the rising costs of care, should increasingly take chronic 
conditions—particularly lipid disorders—into account.
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OBJECTIVES: To examine the association between pre-existing Type 2 Diabetes Mellitus 
(T2DM) and risk of emergency colorectal surgery among elderly patients with colo-
